Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight

COCP stock rallied sharply after hours on 03 Apr 2026, trading at $1.51 after a +48.04% intraday move. The jump follows an FDA Fast Track designation for Cocrystal Pharma’s norovirus candidate and enrollment news from a human challenge study. Volume exploded to 135,319,178 shares, dwarfing the 2,263,335 average volume, and sets up a volatile run into the company’s earnings announcement on 2026-04-06. We use this earnings spotlight to link clinical catalysts to near-term price action and valuation for Cocrystal Pharma (COCP) on the NASDAQ in the United States

COCP stock snapshot and session moves

COCP stock closed the regular session at $1.02 and moved to $1.51 in after hours trading on 03 Apr 2026, a $0.49 gain and +48.04% change. Market cap stands at $15.48M with 10,249,462 shares outstanding. The day range was $1.36–$2.03 and the 52-week range is $0.86–$2.67.

This intraday spike came on outsized volume of 135,319,178 shares, giving traders clear signals of heightened interest ahead of the earnings event

COCP stock drivers: FDA Fast Track and trial news

Regulatory momentum is the immediate driver for COCP stock, after the FDA granted Fast Track for the norovirus program and the company reported enrollment in a Phase 1b human challenge study. These developments can shorten development timelines and attract partnership interest.

Investors should read the full FDA report and company release for details Investing.com FDA Fast Track coverage

COCP stock financials and valuation metrics

Cocrystal Pharma has negative earnings and early-stage revenue metrics; trailing EPS is -0.78 and the reported PE is -1.94. The company shows a price-to-book of 2.67 and a current ratio of 3.68, signaling short-term liquidity.

With no meaningful revenue per share, valuation relies on pipeline probability rather than sales multiples; that increases binary risk around trial and regulatory readouts

COCP stock technicals and trading signals

Technically COCP stock is showing overbought momentum: RSI is 78.81 and MFI is 99.88, both flagging stretched sentiment. Short-term moving averages (50-day $1.03, 200-day $1.23) are below the current price, suggesting recent strength.

High relative volume and RSI overbought readings warn of quick reversals, so traders should size positions for volatility

Meyka AI rates COCP with a score out of 100

Meyka AI rates COCP with a score out of 100: 61.79 / 100 — Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

This proprietary grade balances clinical upside with weak earnings and small market cap; it is informational and not investment advice

Earnings catalysts and timeline for COCP stock

Cocrystal reports earnings on 2026-04-06, a key near-term catalyst that can confirm guidance on cash, R&D progress, and trial timelines. Management commentary on the norovirus Fast Track and the Phase 1b study will be primary focus points.

Watch for updates on cash runway, milestone plans, and any guidance revisions that could materially move COCP stock

Final Thoughts

Key takeaways for COCP stock: the market reacted to regulatory and clinical news with a large after-hours move to $1.51, up 48.04%, but technical indicators show overstretched sentiment. Fundamental ratios remain weak with EPS -0.78 and PE -1.94, leaving valuation tied to pipeline outcomes rather than current earnings. Meyka AI’s forecast model projects a yearly price of $0.39, implying an approximate -48.35% downside versus the current $1.51 price; forecasts are model-based projections and not guarantees. Our proprietary grade is 61.79 (B, HOLD), reflecting potential upside from clinical progress offset by execution and funding risks. Ahead of the 2026-04-06 earnings report, traders should balance position size, use stop limits for downside control, and monitor official releases and SEC filings closely. For context and original coverage see Reuters metrics and the FDA Fast Track note from Investing.com Reuters company metrics and Investing.com FDA Fast Track. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts and grades are for information only and not investment advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.